Gerrit Dispersyn RXI pharmaceuticals NEW Chief Development Officer

RXi Pharmaceuticals announced that Gerrit Dispersyn, Dr. Med Sc. has been appointed as RXi’s Chief Development Officer effective April 24, 2017.

RXi’s current Chief Development Officer, Dr. Pamela Pavco is retiring from its post on May 19, 2017 and  will become a member of the Company’s Scientific Advisory Board where her expertise in the field of oligonucleotides and the development of RNAi therapeutics will continue to support RXi’s ongoing research and development initiatives.

Gerrit Dispersyn, Dr. Med. Sc. is an accomplished leader in clinical, product and business development.  Dr. Dispersyn most recently served as the Vice President, Global Head of Clinical Affairs at Integra LifeSciences Corporation. In this role, Gerrit was responsible for Integra’s global strategy and execution of Clinical Development, Clinical Operations and Medical Affairs projects and a member of Integra’s Senior Management Leadership team, and several of the company’s core teams for M&A projects. Dr. Dispersyn has also been involved in Integra’s research and business activities related to Human Cells, Tissues, and Cellular and Tissue based Products (HCT/Ps), an experience that could be beneficial for RXi’s newly added focus on immuno-oncology and cell therapy. Prior to that role, he was the Vice President, Product Development & Portfolio Management for Barrier Therapeutics, Inc., a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. The company was a spin-out of Johnson & Johnson, and currently part of GlaxoSmithKline.  There he led planning and implementation of all aspects of R&D operations and strategy; scientific, competitive and business intelligence; and alliance management.  Dr. Dispersyn is the founder of Ingress, LLC, a consultancy company providing R&D and clinical operations support to start-up companies, supporting several pharmaceutical drug development programs.  Dr. Dispersyn holds a Dr. Med. Sc. (Ph.D. in Medical Sciences), from the Faculty of Medicine, Maastricht University, Maastricht, the Netherlands, a post-graduate degree in Biomedical Imaging, and a M.Sc. in Biochemistry, both from the University of Antwerp, Belgium.